Biomarkers of eosinophil involvement in allergic and eosinophilic diseases: Review of phenotypic and serum markers including a novel assay to quantify levels of soluble Siglec-8

Journal of Immunological Methods

Volumn 383, Issue 1-2, 2012, Pages 39-46

  Na, Ho Jeong ^a   Hamilton, Robert G ^a   Klion, Amy D ^b   Bochner, Bruce S ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

ELISA; Eosinophil; Granule proteins; Soluble Siglec 8

Indexed keywords

BIOLOGICAL MARKER; FC RECEPTOR; PROTEIN SIGLEC 8; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ALLERGIC DISEASE; ARTICLE; CLINICAL ARTICLE; CLINICAL PRACTICE; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EOSINOPHIL COUNT; EOSINOPHILIA; EOSINOPHILIC GASTROINTESTINAL DISORDER; HUMAN; HYPEREOSINOPHILIA; HYPEREOSINOPHILIC SYNDROME; LEUKOCYTE ACTIVATION; PARASITOSIS; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; QUANTITATIVE ASSAY;

ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CELL SEPARATION; DIAGNOSIS, DIFFERENTIAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; EOSINOPHILIA; EOSINOPHILS; HUMANS; HYPERSENSITIVITY; LECTINS; MARYLAND; PHENOTYPE; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS;

EID: 84864388595     PISSN: 00221759     EISSN: 18727905     Source Type: Journal    
DOI: 10.1016/j.jim.2012.05.017     Document Type: Article

References (74)

1. Ackerman S.J., Bochner B.S. Mechanisms of eosinophilia in the pathogenesis of hypereosinophilic disorders. Immunol. Allergy Clin. North Am. 2007, 27:357.
2. Baigelman W., Chodosh S., Pizzuto D., Cupples L.A. Sputum and blood eosinophils during corticosteroid treatment of acute exacerbations of asthma. Am. J. Med. 1983, 75:929.
3. Bochner B.S. Siglec-8 on human eosinophils and mast cells, and Siglec-F on murine eosinophils, are functionally related inhibitory receptors. Clin. Exp. Allergy 2009, 39:317.
4. Bochner B.S., Gleich G.J. What targeting eosinophils has taught us about their role in diseases. J. Allergy Clin. Immunol. 2010, 126:16.
5. Bochner B.S., Alvarez R.A., Mehta P., Bovin N.V., Blixt O., White J.R., Schnaar R.L. Glycan array screening reveals a candidate ligand for Siglec-8. J. Biol. Chem. 2005, 280:4307.
6. Bolos-Sy A.M., Bochner B.S., Togias A., Schleimer R.P., Beck L.A. Surface expression of CCR3 and CD49d on eosinophils is not increased in allergic asthma and allergic rhinitis. J. Allergy Clin. Immunol. 2000, 105:S259.
7. Busse W.W., Katial R., Gossage D., Sari S., Wang B., Kolbeck R., Coyle A.J., Koike M., Spitalny G.L., Kiener P.A., Geba G.P., Molfino N.A. Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma. J. Allergy Clin. Immunol. 2010, 125:1237.
8. Castro M., Mathur S., Hargreave F., Boulet L.P., Xie F., Young J., Wilkins H.J., Henkel T., Nair P. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am. J. Respir. Crit. Care Med. 2011, 184:1125.
9. Caulfield J.P., Hein A., Rothenberg M.E., Owen W.F., Soberman R.J., Stevens R.L., Austen K.F. A morphometric study of normodense and hypodense human eosinophils that are derived in vivo and in vitro. Am. J. Pathol. 1990, 137:27.
10. Cools J., DeAngelo D.J., Gotlib J., Stover E.H., Legare R.D., Cortes J., Kutok J., Clark J., Galinsky I., Griffin J.D., Cross N.C., Tefferi A., Malone J., Alam R., Schrier S.L., Schmid J., Rose M., Vandenberghe P., Verhoef G., Boogaerts M., Wlodarska I., Kantarjian H., Marynen P., Coutre S.E., Stone R., Gilliland D.G. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N. Engl. J. Med. 2003, 348:1201.
11. Davenpeck K.L., Brummet M.E., Sterbinsky S.A., Mayer R.J., Bochner B.S. Activation of human leukocytes reduces surface P-selectin glycoprotein ligand-1 (PSGl-1, CD162) and adhesion to P-selectin in vitro. J. Immunol. 2000, 165:2764.
12. Douwes J., Gibson P., Pekkanen J., Pearce N. Non-eosinophilic asthma: importance and possible mechanisms. Thorax 2002, 57:643.
13. Ebisawa M., Schleimer R.P., Bickel C., Bochner B.S. Phenotyping of purified human peripheral blood eosinophils using the blind panel mAb. Leukocyte Typing V: White Cell Differentiation Antigens 1995, vol. 1:1036. Oxford University Press, New York.
14. Ebisawa M., Bochner B.S., Schleimer R.P. Eosinophil-endothelial interactions and transendothelial migration. Adhesion molecules in allergic diseases 1997, 173. Marcel Dekker, Inc., New York. B.S. Bochner (Ed.).
15. Fernvik E., Lundahl J., Magnusson C.G., Hallden G. The effect of in vitro activation and platelet interaction on the CD9 distribution and adhesion properties of human eosinophils. Inflamm. Res. 1999, 48:28.
16. Flood-Page P., Menzies-Gow A., Phipps S., Ying S., Wangoo A., Ludwig M.S., Barnes N., Robinson D., Kay A.B. Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. J. Clin. Invest. 2003, 112:1029.
17. Flood-Page P.T., Menzies-Gow A.N., Kay A.B., Robinson D.S. Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am. J. Respir. Crit. Care Med. 2003, 167:199.
18. Floyd H., Ni J., Cornish A.L., Zeng Z., Liu D., Carter K.C., Steel J., Crocker P.R. Siglec-8: a novel eosinophil-specific member of the immunoglobulin superfamily. J. Biol. Chem. 2000, 275:861.
19. Georas S.N., Liu M.C., Newman W., Beall W.D., Stealey B.A., Bochner B.S. Altered adhesion molecule expression and endothelial activation accompany the recruitment of human granulocytes to the lung following segmental antigen challenge. Am. J. Respir. Cell Mol. Biol. 1992, 7:261.
20. Gevaert P., Lang-Loidolt D., Lackner A., Stammberger H., Staudinger H., Van Zele T., Holtappels G., Tavernier J., van Cauwenberge P., Bachert C. Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps. J. Allergy Clin. Immunol. 2006, 118:1133.
21. Gevaert P., Van Bruaene N., Cattaert T., Van Steen K., Van Zele T., Acke F., De Ruyck N., Blomme K., Sousa A.R., Marshall R.P., Bachert C. Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis. J. Allergy Clin. Immunol. 2011, 128:989. (e1-8).
22. Gibson P.G., Dolovich J., Girgis-Gabardo A., Morris M.M., Anderson M., Hargreave F.E., Denburg J.A. The inflammatory response in asthma exacerbation - changes in circulating eosinophils, basophils and their progenitors. Clin. Exp. Allergy 1990, 20:661.
23. Haldar P., Brightling C.E., Hargadon B., Gupta S., Monteiro W., Sousa A., Marshall R.P., Bradding P., Green R.H., Wardlaw A.J., Pavord I.D. Mepolizumab and exacerbations of refractory eosinophilic asthma. N. Engl. J. Med. 2009, 360:973.
24. Hijnen D., De Bruin-Weller M., Oosting B., Lebre C., De Jong E., Bruijnzeel-Koomen C., Knol E. Serum thymus and activation-regulated chemokine (TARC) and cutaneous T cell- attracting chemokine (CTACK) levels in allergic diseases: TARC and CTACK are disease-specific markers for atopic dermatitis. J. Allergy Clin. Immunol. 2004, 113:334.
25. Hogan S.P., Rosenberg H.F., Moqbel R., Phipps S., Foster P.S., Lacy P., Kay A.B., Rothenberg M.E. Eosinophils: biological properties and role in health and disease. Clin. Exp. Allergy 2008, 38:709.
26. Jahnsen F.L., Brandtzaeg P., Halstensen T.S. Monoclonal antibody EG2 does not provide reliable immunohistochemical discrimination between resting and activated eosinophils. J. Immunol. Methods 1994, 175:23.
27. Johansson M.W., Barthel S.R., Swenson C.A., Evans M.D., Jarjour N.N., Mosher D.F., Busse W.W. Eosinophil beta 1 integrin activation state correlates with asthma activity in a blind study of inhaled corticosteroid withdrawal. J. Allergy Clin. Immunol. 2006, 117:1502.
28. Johansson M.W., Kelly E.A., Busse W.W., Jarjour N.N., Mosher D.F. Up-regulation and activation of eosinophil integrins in blood and airway after segmental lung antigen challenge. J. Immunol. 2008, 180:7622.
29. Johansson M.W., Han S.T., Gunderson K.A., Busse W.W., Jarjour N.N., Mosher D.F. Platelet activation, P-selectin, and eosinophil beta1-integrin activation in asthma. Am. J. Respir. Crit. Care Med. 2012, 185:498.
30. Julius P., Luttmann W., Knoechel B., Kroegel C., Matthys H., Virchow J.C. CD69 surface expression on human lung eosinophils after segmental allergen provocation. Eur. Respir. J. 1999, 13:1253.
31. Kahn J.E., Grandpeix-Guyodo C., Marroun I., Catherinot E., Mellot F., Roufosse F., Blétry O. Sustained response to mepolizumab in refractory Churg-Strauss syndrome. J. Allergy Clin. Immunol. 2010, 125:267.
32. Kay A.B., Klion A.D. Anti-interleukin-5 therapy for asthma and hypereosinophilic syndrome. Immunol. Allergy Clin. North Am. 2004, 24:645.
33. Kayaba H., Yamada Y., Cui C.H., Saito N., Honda K., Kobayashi Y., Urayama O., Chihara J. Expression of VLA-4 on eosinophils decreases in patients with eosinophilia. Int. Arch. Allergy Immunol. 2001, 125:33.
34. Kikly K.K., Bochner B.S., Freeman S., Tan K.B., Gallagher K.T., D'Alessio K., Holmes S.D., Abrahamson J., Hopson C.B., Fischer E.I., Erickson-Miller C.L., Tachimoto H., Schleimer R.P., White J.R. Identification of SAF-2, a novel siglec expressed on eosinophils, mast cells and basophils. J. Allergy Clin. Immunol. 2000, 105:1093.
35. Kim S., Marigowda G., Oren E., Israel E., Wechsler M. Mepolizumab as a steroid-sparing treatment in patients with Churg-Strauss syndrome. J. Allergy Clin. Immunol. 2010, 125:1336.
36. Kita H., Adolphson C.R., Gleich G.J. Biology of eosinophils. Allergy Principles and Practice 2003, 305. Mosby, Philadelphia. 6th edition. J.N.F. Adkinson, J.W. Yunginger, W.W. Busse, B.S. Bochner, S.T. Holgate, F.E.R. Simons (Eds.).
37. Koh G.C., Shek L.P., Goh D.Y., Van Bever H., Koh D.S. Eosinophil cationic protein: is it useful in asthma? A systematic review. Respir. Med. 2007, 101:696.
38. Konikoff M.R., Blanchard C., Kirby C., Buckmeier B.K., Cohen M.B., Heubi J.E., Putnam P.E., Rothenberg M.E. Potential of blood eosinophils, eosinophil-derived neurotoxin, and eotaxin-3 as biomarkers of eosinophilic esophagitis. Clin. Gastroenterol. Hepatol. 2006, 4:1328.
39. Luijk B., Lindemans C.A., Kanters D., van der Heijde R., Bertics P., Lammers J.W., Bates M.E., Koenderman L. Gradual increase in priming of human eosinophils during extravasation from peripheral blood to the airways in response to allergen challenge. J. Allergy Clin. Immunol. 2005, 115:997.
40. Matsumoto K., Sterbinsky S.A., Bickel C.A., Zhou D.W., Kovach N.L., Bochner B.S. Regulation of α4 integrin-mediated adhesion of human eosinophils to fibronectin and vascular cell adhesion molecule-1 (VCAM-1). J. Allergy Clin. Immunol. 1997, 99:648.
41. Matsumoto K., Appiah-Pippim J., Schleimer R.P., Bickel C.A., Beck L.A., Bochner B.S. CD44 and CD69 represent different types of cell surface activation markers for human eosinophils. Am. J. Respir. Cell Mol. Biol. 1998, 18:860.
42. Mawhorter S.D., Stephany D.A., Ottesen E.A., Nutman T.B. Identification of surface molecules associated with physiologic activation of eosinophils - application of whole-blood flow cytometry to eosinophils. J. Immunol. 1996, 156:4851.
43. Menzies-Gow A., Flood-Page P., Sehmi R., Burman J., Hamid Q., Robinson D.S., Kay A.B., Denburg J. Anti-IL-5 (mepolizumab) therapy induces bone marrow eosinophil maturational arrest and decreases eosinophil progenitors in the bronchial mucosa of atopic asthmatics. J. Allergy Clin. Immunol. 2003, 111:714.
44. Nair P., Pizzichini M.M., Kjarsgaard M., Inman M.D., Efthimiadis A., Pizzichini E., Hargreave F.E., O'Byrne P.M. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N. Engl. J. Med. 2009, 360:985.
45. Nakajima H., Loegering D.A., Kita H., Kephart G.M., Gleich G.J. Reactivity of monoclonal antibodies EG1 and EG2 with eosinophils and their granule proteins. J. Leukoc. Biol. 1999, 66:447.
46. Nishikawa K., Morii T., Ako H., Hamada K., Saito S., Narita N. In vivo expression of CD69 on lung eosinophils in eosinophilic pneumonia - CD69 as a possible activation marker for eosinophils. J. Allergy Clin. Immunol. 1992, 90:169.
47. Nutku E., Aizawa H., Hudson S.A., Bochner B.S. Ligation of Siglec-8: a selective mechanism for induction of human eosinophil apoptosis. Blood 2003, 101:5014.
48. Ogbogu P.U., Bochner B.S., Butterfield J.H., Gleich G.J., Huss-Marp J., Kahn J.E., Leiferman K.M., Nutman T.B., Pfab F., Ring J., Rothenberg M.E., Roufosse F., Sajous M.H., Sheikh J., Simon D., Simon H.U., Stein M.L., Wardlaw A., Weller P.F., Klion A.D. Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy. J. Allergy Clin. Immunol. 2009, 124:1319.
49. Phipps S., Flood-Page P., Menzies-Gow A., Ong Y.E., Kay A.B. Intravenous anti-IL-5 monoclonal antibody reduces eosinophils and tenascin deposition in allergen-challenged human atopic skin. J. Invest. Dermatol. 2004, 122:1406.
50. Pignatti P., Perfetti L., Galdi E., Pozzi V., Bossi A., Biale C., Moscato G. Increased CD69 expression on peripheral blood eosinophils after specific inhalation challenge. Allergy 2002, 57:411.
51. Rothenberg M.E., Hogan S.P. The eosinophil. Annu. Rev. Immunol. 2006, 24:147.
52. Rothenberg M.E., Owen W.F., Silberstein D.S., Woods J., Soberman R.J., Austen K.F., Stevens R.L. Human eosinophils have prolonged survival, enhanced functional properties, and become hypodense when exposed to human interleukin 3. J. Clin. Invest. 1988, 81:1986.
53. Rothenberg M.E., Klion A.D., Roufosse F.E., Kahn J.E., Weller P.F., Simon H.U., Schwartz L.B., Rosenwasser L.J., Ring J., Griffin E.F., Haig A.E., Frewer P.I., Parkin J.M., Gleich G.J. Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N. Engl. J. Med. 2008, 358:1215.
54. Simon D., Wardlaw A., Rothenberg M.E. Organ-specific eosinophilic disorders of the skin, lung and gastrointestinal tract. J. Allergy Clin. Immunol. 2010, 126:45.
55. Spergel J.M., Rothenberg M.E., Collins M.H., Furuta G.T., Markowitz J.E., Fuchs G., O'Gorman M.A., Abonia J.P., Young J., Henkel T., Wilkins H.J., Liacouras C.A. Reslizumab in children and adolescents with eosinophilic esophagitis: Results of a double-blind, randomized, placebo-controlled trial. J. Allergy Clin. Immunol. 2012, 129:456.
56. Stein M.L., Collins M.H., Villanueva J.M., Kushner J.P., Putnam P.E., Buckmeier B.K., Filipovich A.H., Assa'ad A.H., Rothenberg M.E. Anti-IL-5 (mepolizumab) therapy for eosinophilic esophagitis. J. Allergy Clin. Immunol. 2006, 118:1312.
57. Stein M.L., Villanueva J.M., Buckmeier B.K., Yamada Y., Filipovich A.H., Assa'ad A.H., Rothenberg M.E. Anti-IL-5 (mepolizumab) therapy reduces eosinophil activation ex vivo and increases IL-5 and IL-5 receptor levels. J. Allergy Clin. Immunol. 2008, 121:1473.
58. Stevens W.W., Kim T.S., Pujanauski L.M., Hao X., Braciale T.J. Detection and quantitation of eosinophils in the murine respiratory tract by flow cytometry. J. Immunol. Methods 2007, 327:63.
59. Straumann A., Conus S., Grzonka P., Kita H., Kephart G., Bussmann C., Beglinger C., Smith D.A., Patel J., Byrne M., Simon H.U. Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial. Gut 2009, 59:21.
60. Suzukawa M., Koketsu R., Iikura M., Nakae S., Matsumoto K., Nagase H., Saito H., Matsushima K., Ohta K., Yamamoto K., Yamaguchi M. Interleukin-33 enhances adhesion, CD11b expression and survival in human eosinophils. Lab. Invest. 2008, 88:1245.
61. Tai P.C., Spry C.J., Peterson C., Venge P., Olsson I. Monoclonal antibodies distinguish between storage and secreted forms of eosinophil cationic protein. Nature 1984, 309:182.
62. Tateno H., Crocker P.R., Paulson J.C. Mouse Siglec-F and human Siglec-8 are functionally convergent paralogs that are selectively expressed on eosinophils and recognize 6'-sulfo-sialyl Lewis X as a preferred glycan ligand. Glycobiology 2005, 15:1125.
63. Tateno H., Li H., Schur M.J., Bovin N., Crocker P.R., Wakarchuk W.W., Paulson J.C. Distinct endocytic mechanisms of CD22 (Siglec-2) and Siglec-F reflect roles in cell signaling and innate immunity. Mol. Cell. Biol. 2007, 27:5699.
64. Vardiman J., Hyjek E. World health organization classification, evaluation, and genetics of the myeloproliferative neoplasm variants. Hematology Am. Soc. Hematol. Educ. Program 2011, 2011:250.
65. Varki A., Angata T. Siglecs - the major sub-family of I-type lectins. Glycobiology 2006, 16:1R.
66. Voehringer D., van Rooijen N., Locksley R.M. Eosinophils develop in distinct stages and are recruited to peripheral sites by alternatively activated macrophages. J. Leukoc. Biol. 2007, 81:1434.
67. von Gunten S., Bochner B.S. Basic and clinical immunology of siglecs. Ann. N. Y. Acad. Sci. 2008, 1143:61.
68. Wedi B., Wieczorek D., Stünkel T., Breuer K., Kapp A. Staphylococcal exotoxins exert proinflammatory effects through inhibition of eosinophil apoptosis, increased surface antigen expression (CD11b, CD45, CD54, and CD69), and enhanced cytokine-activated oxidative burst, thereby triggering allergic inflammatory reactions. J. Allergy Clin. Immunol. 2002, 109:477.
69. Werfel S., Yednock T., Matsumoto K., Sterbinsky S.A., Schleimer R.P., Bochner B.S. Functional regulation of b1 integrins and human eosinophils by divalent cations and cytokines. Am. J. Respir. Cell Mol. Biol. 1996, 14:45.
70. Wilson T.M., Maric I., Shukla J., Brown M., Santos C., Simakova O., Khoury P., Fay M.P., Kozhich A., Kolbeck R., Metcalfe D.D., Klion A.D. IL-5 receptor alpha levels in patients with marked eosinophilia or mastocytosis. J. Allergy Clin. Immunol. 2011, 128:1086. (e1-3).
71. Wu D., Molofsky A.B., Liang H.E., Ricardo-Gonzalez R.R., Jouihan H.A., Bando J.K., Chawla A., Locksley R.M. Eosinophils sustain adipose alternatively activated macrophages associated with glucose homeostasis. Science 2011, 332:243.
72. Yokoi H., Choi O.H., Hubbard W., Lee H.-S., Canning B.J., Lee H.H., Ryu S.-D., Bickel C.A., Hudson S.A., MacGlashan D.W., Bochner B.S. Inhibition of FcεRI-dependent mediator release and calcium flux from human mast cells by Siglec-8 engagement. J. Allergy Clin. Immunol. 2008, 121:499.
73. Yoon J., Terada A., Kita H. CD66b regulates adhesion and activation of human eosinophils. J. Immunol. 2007, 179:8454.
74. Zimmerman B., Lanner A., Enander I., Zimmerman R.S., Peterson C.G., Ahlstedt S. Total blood eosinophils, serum eosinophil cationic protein and eosinophil protein X in childhood asthma: relation to disease status and therapy. Clin. Exp. Allergy 1993, 23:564.